8-K: BioAtla Faces Nasdaq Delisting, Pursues 1-for-50 Reverse Split

BioAtla faces Nasdaq delisting after a policy change on super-voting stock, prompting a new 1-for-50 reverse stock split via merger and securing a $5 million investment.

Summary

• BioAtla failed to secure sufficient common stockholder votes for a reverse stock split (1-for-5 to 1-for-20) despite issuing a super-voting Series A Junior Preferred Stock to achieve the required 2/3 majority.
• Nasdaq informed BioAtla that using super-voting preferred stock for reverse splits is now considered a violation of its Voting Rights Rule (5640), overturning previous guidance without public notice.
• To address listing compliance and achieve a share reduction, BioAtla entered into a merger agreement with a wholly-owned subsidiary to effect a 1-for-50 reverse stock split, requiring only a majority vote of common stockholders.
• The company received confirmation that Alliance International Resources Corp. (AIRC) will complete its investment in Inversagen AI, leading to a $5 million payment to BioAtla for common units in BA 3021 SPV LLC.
• BioAtla is actively working to regain compliance with Nasdaq's $1.00 bid price and $2.5 million stockholders' equity (or $35 million MVLS) rules by February 2, 2026, after Nasdaq denied a previous compliance determination despite 64 consecutive days of meeting the MVLS rule.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing negatively due to the significant corporate governance challenges, the imminent delisting threat from Nasdaq, and the unexpected policy shift by the exchange, which collectively create substantial uncertainty for investors.

Positives

• Secured a $5 million investment from Inversagen AI for common units in BA 3021 SPV LLC, subject to AIRC's investment completion.
• Filed a new Form S-3 shelf registration to maintain continuous flexibility for future securities offerings.
• The Board is actively pursuing an alternative strategy (merger) to achieve a reverse stock split and address Nasdaq listing requirements, demonstrating proactive management.

Negatives

• Failed to obtain the necessary 2/3 common stockholder approval for the initial reverse stock split proposal, indicating significant retail stockholder non-participation.
• Nasdaq's unannounced policy change regarding super-voting preferred stock use for reverse splits directly impacted BioAtla's strategy and could lead to a delisting violation.
• Nasdaq denied BioAtla's request for compliance determination on January 13, 2026, despite the company evidencing compliance with the MVLS Rule for 64 consecutive trading days.
• The company faces an imminent delisting threat from Nasdaq if it cannot regain compliance with the Bid Price Rule and Equity/MVLS Rule by February 2, 2026.
• The potential delisting to OTC Markets could materially adversely affect the stock's trading price and volume.

Risks

• Inability to regain compliance with Nasdaq's Bid Price Rule and Equity/MVLS Rule by February 2, 2026, leading to suspension and delisting.
• The potential delisting from Nasdaq could result in a material adverse effect on the trading price and volume of common stock, making it more difficult for stockholders to sell shares.
• Uncertainty regarding the timing and completion of the alternative merger transaction for the reverse stock split.
• The company's ability to continue as a going concern and its need for additional funding to continue development of its CAB technology platform and product candidates.
• Risks associated with clinical and preclinical trials, including potential delays, uncertainties in R&D, and regulatory approval processes.
• Dependence on the success of its CAB technology platform and ability to enroll patients in trials.
• Reliance on third parties for manufacturing, supply, and conducting clinical trials.
• Potential adverse impacts due to geopolitical or macroeconomic events.

Future Outlook

The company intends to proceed with an alternative merger transaction to effect a 1-for-50 reverse stock split to address Nasdaq listing requirements. It also plans to appeal any delisting determination from Nasdaq. The company maintains continuous flexibility for future securities offerings through its new Form S-3 shelf registration. Management acknowledges the need for additional funding to continue developing its CAB technology platform and product candidates.

Management Comments

• "The Company believes that obtaining the approval of stockholders with the Series A Preferred Share complies with the Voting Rights Rule and is in compliance with Nasdaq's policy as set forth in its Staff Interpretative Letter issued in 2022 (the 2022 Guidance)."
• "The Company believes that Nasdaq's delay in the consideration and confirmation of the Company's compliance status, its subsequent failure to issue a determination that the Company had regained compliance with the MVLS Rule, as well as Nasdaq's recent decision to overturn longstanding Nasdaq policy regarding the use of super-voting stock to achieve quorum and thereby seek to obtain shareholder approval for a reverse stock split, has and will cause the Company irreparable harm."
• "The Company intends to request that the Council call for review any decision by the Panel to delist the Company."

Industry Context

StockSavvy.ai notes that BioAtla's situation highlights increasing scrutiny from Nasdaq on corporate governance practices, particularly regarding the use of super-voting shares to bypass common shareholder dissent on critical matters like reverse stock splits. This unannounced policy shift by Nasdaq could set a precedent, impacting other companies that might consider similar mechanisms to maintain listing compliance. The $5 million investment, while positive, is a relatively small capital injection for a biotech company, suggesting ongoing funding challenges in a competitive and capital-intensive industry.

Comparison to Industry Standards

• The 1-for-50 reverse stock split ratio is significantly higher than typical reverse splits seen in the biotech sector, which often range from 1-for-5 to 1-for-10. For example, companies like Athersys (ATHX) or Sorrento Therapeutics (SRNEQ) have implemented reverse splits, but a 1-for-50 ratio indicates a more severe need to boost share price to meet listing requirements.
• Nasdaq's unannounced policy change on super-voting preferred stock is an unusual regulatory move. Historically, exchanges have provided clear guidance or public notices for such significant policy shifts, unlike the situation described by BioAtla. This lack of transparency from Nasdaq is not standard practice for major exchange rule interpretations.
• The company's struggle to maintain Nasdaq listing, despite evidencing compliance with MVLS for 64 days, suggests a more stringent application of discretionary rules by Nasdaq staff compared to what might be expected based on the stated "generally no more than 20 consecutive business days" guideline.

Corporate Governance

Stakeholder Impact

• Shareholders: Face significant uncertainty regarding the company's Nasdaq listing, potential delisting to OTC Markets, and the impact of a 1-for-50 reverse stock split on share price and liquidity. The failure of the initial reverse split and Nasdaq's policy change highlight governance challenges.
• Management/Board: Actively working to navigate complex regulatory challenges and implement strategic corporate actions to maintain listing and secure funding.
• Nasdaq: Faces scrutiny for its unannounced policy change and its handling of BioAtla's compliance determination, potentially impacting its reputation for transparent rule-making.

Next Steps

• Hold a special meeting of stockholders to vote on the Merger Agreement for the 1-for-50 reverse stock split.
• Continue efforts to evidence compliance with Nasdaq's Bid Price Rule and Equity/MVLS Rule by February 2, 2026.
• If delisted, the company intends to request that the Nasdaq Listing and Hearing Review Council call for a review of any delist determination.
• Complete the investment from Inversagen AI, LLC, following AIRC's investment.
• Await the SEC's declaration of effectiveness for the new Form S-3 shelf registration statement.

Key Dates

Recommendation

The company faces an imminent delisting from Nasdaq, which would severely impact liquidity and likely lead to a significant drop in share price. Nasdaq's unannounced policy change and the company's struggle to meet listing requirements, despite proactive measures, indicate deep-seated issues and regulatory friction. While a $5 million investment is positive, it is insufficient to offset the severe risks associated with delisting and the ongoing need for substantial funding for a biotech company. The proposed 1-for-50 reverse stock split, while a necessary step to attempt to regain compliance, often signals underlying financial distress and can lead to further share price erosion post-split.

Keywords

BioAtla, BCAB, Nasdaq, delisting, reverse stock split, merger, corporate governance, SEC filing, 8-K, capital raise, Inversagen AI, shelf registration, voting rights, preferred stock, biotech, pharmaceutical